Press/Media
- 1 - 25 out of 306 results
Search results
-
Weekly: Karyopharm Therapeutics (KPTI: 62.0c) down 11% in 2 weeks; -0.21c [0.3%]
8/02/25
1 item of Media coverage
Press/Media
-
-
Monthly: Karyopharm Therapeutics (KPTI: 62.21c) continues significant downtrend; falls 9%
3/02/25
1 item of Media coverage
Press/Media
-
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
29/01/25
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 70.0c) gains 6% on weak volume; +4c [6.1%]
25/01/25
1 item of Media coverage
Press/Media
-
Swedish Orphan Biovitrum : Sobi's Q2 2023 report, 18 July
21/01/25
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 66.0c) sinks 8% on weak volume; -5.86c [8.2%]
18/01/25
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 72.0c) tumbles 11% on weak volume; -9c [11.1%]
11/01/25
1 item of Media coverage
Press/Media
-
Karyopharm Therapeutics increases 5.3% in 2025, but lagging Healthcare-Products sector
10/01/25
1 item of Media coverage
Press/Media
-
-
John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib
4/01/25
1 item of Media coverage
Press/Media
-
John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment
4/01/25
1 item of Media coverage
Press/Media
-
Managing Treatment-Emergent Anemia in a Patient With Myelofibrosis
4/01/25
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 77.0c) surges 10% on below average volume; +7c [10.0%]
4/01/25
1 item of Media coverage
Press/Media
-
Monthly: Karyopharm Therapeutics (KPTI: 68.0c) plunges 20%, trailing 69% of stocks
2/01/25
1 item of Media coverage
Press/Media
-
End-of-Quarter Synopsis Monthly : Karyopharm Therapeutics (KPTI: 68.0c) plunges 20%, trailing 69% of stocks
31/12/24
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 70.0c) surges 11% on average volume; +7c [11.1%]
28/12/24
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 63.0c) tumbles 10%; -7c [10.0%]
21/12/24
1 item of Media coverage
Press/Media
-
Findings from Icahn School of Medicine at Mount Sinai Broaden Understanding of Myelofibrosis (Systematic Review and Meta-Analysis of Spleen Volume Reduction and Overall Survival in Myelofibrosis Patients Treated with JAK-Inhibitors)
Sastow , D., Mazumdar, M., Tremblay, D. & Mascarenhas, J.
19/12/24
1 item of Media coverage
Press/Media
-
Weekly: Karyopharm Therapeutics (KPTI: 70.0c) sinks 9% on thin volume; -6.82c [8.9%]
14/12/24
1 item of Media coverage
Press/Media
-